46th Annual William Blair Growth Stock Conference
Logotype for Stevanato Group S.p.A.

Stevanato Group (STVN) 46th Annual William Blair Growth Stock Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Stevanato Group S.p.A.

46th Annual William Blair Growth Stock Conference summary

2 Jun, 2026

Company overview and strategic positioning

  • Over 75 years of history, specializing in glass containers for the pharmaceutical industry, with a mission-critical role in biopharma supply chains.

  • Achieved steady double-digit growth, expanding from €18 million in 2000 to a guided €1.3 billion in 2025 revenue, with EBITDA consistently above 25%.

  • Market leader in cartridges and ready-to-use vials, and second globally in syringes, focusing on partnerships with the top 25 pharma companies.

  • Emphasizes end-to-end value proposition, offering primary packaging, drug delivery systems, and engineering solutions.

  • Maintains a global manufacturing footprint with 13 sites in nine countries, ensuring consistent quality and supply chain reliability.

Product innovation and R&D

  • Developed proprietary EZ-fill technology for syringes, cartridges, and vials, supported by a robust IP portfolio.

  • R&D centers in Italy and Boston enable early-stage collaboration with pharma clients, tailoring products for phase II/III and commercial launches.

  • Focused on high-value products such as auto-injectors and pens, addressing the shift toward self-medication and biologics.

  • Ongoing investments in sophisticated coatings and large-volume devices to meet rising demand in the biologics sector.

  • M&A activity targets specialized competencies to enhance the product portfolio.

Capacity expansion and capital allocation

  • Major investments post-IPO, including over €500 million in a new Fishers, Indiana facility and expanded capacity in Italy and Germany.

  • 70% of $1.2 billion IPO proceeds reinvested to support extraordinary CapEx cycles and global capacity growth.

  • Plans to reduce CapEx to 10%-12% of revenue by 2027, aiming to generate significant free cash flow.

  • Flexible manufacturing allows rapid adaptation between syringes and cartridges to match market shifts.

  • Greenfield plants mirror customer supply chains, supporting global pharma partners with consistent quality.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more